Stereotaxis Reports 2025 Second Quarter Financial Results
Stereotaxis (NYSE: STXS), a pioneer in surgical robotics, reported its Q2 2025 financial results with significant growth. Total revenue reached $8.8 million, up 95% year-over-year and 18% sequentially. System revenue was $3.0 million, while recurring revenue grew 35% to $5.8 million.
The company achieved a notable milestone with FDA clearance of MAGiC Sweep, its first interventional catheter approval in nearly 20 years. Gross margin was 52%, with recurring revenue margin at 68% and system margin at 22%. The quarter ended with $7.0 million in cash, subsequently strengthened by a $12.5 million strategic financing in July.
Management reiterated expectations of double-digit revenue growth for 2025, projecting $2-3 million quarterly system revenue and recurring revenue scaling to $7 million by Q4 2025.
Stereotaxis (NYSE: STXS), pioniere nella robotica chirurgica, ha comunicato i risultati finanziari del secondo trimestre 2025 con una crescita significativa. Il fatturato totale ha raggiunto 8,8 milioni di dollari, in aumento del 95% rispetto all'anno precedente e del 18% rispetto al trimestre precedente. Il fatturato derivante dai sistemi è stato di 3,0 milioni di dollari, mentre i ricavi ricorrenti sono cresciuti del 35%, raggiungendo 5,8 milioni di dollari.
L'azienda ha raggiunto un traguardo importante con l'approvazione FDA di MAGiC Sweep, il suo primo catetere interventistico approvato dopo quasi 20 anni. Il margine lordo è stato del 52%, con un margine sui ricavi ricorrenti del 68% e un margine sui sistemi del 22%. Il trimestre si è chiuso con 7,0 milioni di dollari in cassa, successivamente rafforzati da un finanziamento strategico di 12,5 milioni di dollari a luglio.
La direzione ha ribadito le aspettative di una crescita a doppia cifra dei ricavi per il 2025, prevedendo un fatturato trimestrale dai sistemi tra 2 e 3 milioni di dollari e un aumento dei ricavi ricorrenti fino a 7 milioni di dollari entro il quarto trimestre 2025.
Stereotaxis (NYSE: STXS), pionera en robótica quirúrgica, reportó sus resultados financieros del segundo trimestre de 2025 con un crecimiento significativo. Los ingresos totales alcanzaron 8,8 millones de dólares, un aumento del 95% interanual y del 18% secuencial. Los ingresos por sistemas fueron de 3,0 millones de dólares, mientras que los ingresos recurrentes crecieron un 35%, llegando a 5,8 millones de dólares.
La compañía logró un hito importante con la aprobación de la FDA para MAGiC Sweep, su primer catéter intervencionista aprobado en casi 20 años. El margen bruto fue del 52%, con un margen del 68% en ingresos recurrentes y un margen del 22% en sistemas. El trimestre cerró con 7,0 millones de dólares en efectivo, reforzado posteriormente por una financiación estratégica de 12,5 millones de dólares en julio.
La gerencia reiteró las expectativas de un crecimiento de ingresos de dos dígitos para 2025, proyectando ingresos trimestrales por sistemas entre 2 y 3 millones de dólares y un aumento de los ingresos recurrentes hasta 7 millones de dólares para el cuarto trimestre de 2025.
Stereotaxis (NYSE: STXS), 수술용 로봇 분야의 선구자인 이 회사는 2025년 2분기 재무 실적에서 큰 성장을 보고했습니다. 총 매출은 880만 달러로 전년 대비 95%, 전분기 대비 18% 증가했습니다. 시스템 매출은 300만 달러였으며, 반복 매출은 35% 증가하여 580만 달러를 기록했습니다.
회사는 거의 20년 만에 첫 중재용 카테터 승인인 MAGiC Sweep의 FDA 승인을 획득하는 중요한 이정표를 달성했습니다. 총 이익률은 52%였으며, 반복 매출 이익률은 68%, 시스템 이익률은 22%였습니다. 분기 말 현금은 700만 달러였으며, 7월에는 전략적 자금 조달로 1250만 달러가 추가되었습니다.
경영진은 2025년 두 자릿수 매출 성장 기대를 재확인하며, 분기별 시스템 매출을 200만~300만 달러로, 2025년 4분기까지 반복 매출을 700만 달러까지 확대할 전망입니다.
Stereotaxis (NYSE : STXS), pionnier dans la robotique chirurgicale, a publié ses résultats financiers du deuxième trimestre 2025 avec une croissance significative. Le chiffre d'affaires total a atteint 8,8 millions de dollars, en hausse de 95 % en glissement annuel et de 18 % séquentiellement. Le chiffre d'affaires des systèmes s'est élevé à 3,0 millions de dollars, tandis que les revenus récurrents ont augmenté de 35 % pour atteindre 5,8 millions de dollars.
L'entreprise a franchi une étape importante avec l'approbation par la FDA de MAGiC Sweep, son premier cathéter interventionnel approuvé depuis près de 20 ans. La marge brute était de 52 %, avec une marge sur les revenus récurrents de 68 % et une marge sur les systèmes de 22 %. Le trimestre s'est terminé avec 7,0 millions de dollars en liquidités, renforcées par un financement stratégique de 12,5 millions de dollars en juillet.
La direction a réitéré ses prévisions de croissance à deux chiffres du chiffre d'affaires pour 2025, projetant un chiffre d'affaires trimestriel des systèmes entre 2 et 3 millions de dollars et une augmentation des revenus récurrents à 7 millions de dollars d'ici le quatrième trimestre 2025.
Stereotaxis (NYSE: STXS), ein Pionier im Bereich der chirurgischen Robotik, meldete seine Finanzergebnisse für das zweite Quartal 2025 mit erheblichem Wachstum. Der Gesamtumsatz erreichte 8,8 Millionen US-Dollar, ein Anstieg von 95 % im Jahresvergleich und 18 % gegenüber dem Vorquartal. Der Systemumsatz betrug 3,0 Millionen US-Dollar, während der wiederkehrende Umsatz um 35 % auf 5,8 Millionen US-Dollar wuchs.
Das Unternehmen erreichte einen wichtigen Meilenstein mit der FDA-Zulassung von MAGiC Sweep, seiner ersten Zulassung für einen interventionellen Katheter seit fast 20 Jahren. Die Bruttomarge lag bei 52%, mit einer Marge von 68 % bei den wiederkehrenden Umsätzen und 22 % beim Systemumsatz. Das Quartal endete mit 7,0 Millionen US-Dollar in bar, die im Juli durch eine strategische Finanzierung von 12,5 Millionen US-Dollar weiter gestärkt wurden.
Das Management bekräftigte die Erwartungen eines zweistelligen Umsatzwachstums für 2025 und prognostizierte einen vierteljährlichen Systemumsatz von 2 bis 3 Millionen US-Dollar sowie ein Wachstum der wiederkehrenden Umsätze auf 7 Millionen US-Dollar bis zum vierten Quartal 2025.
- Revenue grew 95% year-over-year to $8.8 million
- Recurring revenue increased 35% to $5.8 million
- FDA clearance achieved for MAGiC Sweep catheter
- Secured $12.5 million in strategic financing
- Strong recurring revenue gross margin of 68%
- Operating loss of $4.0 million in Q2
- Negative free cash flow of $3.7 million
- Low system gross margin of 22%
- Cash position decreased to $7.0 million before financing
- Net loss of $3.8 million in Q2
Insights
Stereotaxis shows strong revenue growth with key product launches, but still operating at a loss despite improvement.
Stereotaxis posted 95% year-over-year revenue growth to
The company's gross margin stands at
Despite the revenue growth, Stereotaxis is still operating at a loss with an operating loss of
The company's cash position of
The revenue growth trajectory looks promising with management guiding to double-digit revenue growth for full-year 2025, forecasting system revenue of
This quarter represents a significant inflection point, with innovations finally translating to commercial adoption after years of R&D investment. The key metrics to watch going forward are: 1) recurring revenue growth acceleration toward the
ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2025.
“We are pleased with our commercial results in the quarter. Sequential and year-over-year growth in both recurring and system revenue reflects the early positive impact of our innovations on commercial adoption,” said David Fischel, Chairman and CEO. “This is an exciting milestone rich year with broad-based progress across the late stages of our comprehensive innovation strategy.”
“Recent FDA clearance of MAGiC Sweep was a significant milestone as Stereotaxis’ first FDA clearance for an interventional catheter in nearly 20 years. Initial sales of MAGiC Sweep this quarter will contribute, along with MAGiC and Map-iT, to ramping recurring revenue. We are proud of our recent regulatory successes and continue to expect multiple additional regulatory approvals in the coming weeks and months, in line with previously shared timelines. As we reach key regulatory milestones we are beginning to demonstrate the initial commercial impact of these innovations in supporting revenue growth, improved margins, and earnings accretion.”
“Our progress in establishing a new foundational product ecosystem is transformational clinically, commercially and strategically. Our recently completed equity financing offers us a strengthened balance sheet with which to accelerate adoption of our comprehensive innovation strategy as we reach key milestones. This is a critical year in which we are establishing the healthy foundations for a preeminent high-growth robotic surgery company.”
2025 Second Quarter Financial Results
Revenue for the second quarter of 2025 totaled
Gross margin for the second quarter was
Operating expenses in the second quarter of
Operating loss and net loss in the second quarter of 2025 were (
Cash Balance and Liquidity
At June 30, 2025, Stereotaxis had cash and cash equivalents of
Forward Looking Expectations
Stereotaxis reiterates its expectation of double-digit revenue growth for the full year 2025, with system revenue of
Conference Call and Webcast
Stereotaxis will host a conference call and webcast today, August 7, 2025, at 4:30 p.m. Eastern Time. To access the conference call, dial 888-596-4144 (US and Canada) or 1-646-968-2525 (International) and give the participant pass code 1064613. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions, including tariffs, on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Company Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly R. Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
| STEREOTAXIS, INC. | |||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (Unaudited) | |||||||||||||||
| (in thousands, except share and per share amounts) | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue: | |||||||||||||||
| Systems | $ | 3,038 | $ | 240 | $ | 5,002 | $ | 2,852 | |||||||
| Disposables, service and accessories | 5,760 | 4,262 | 11,268 | 8,530 | |||||||||||
| Total revenue | 8,798 | 4,502 | 16,270 | 11,382 | |||||||||||
| Cost of revenue: | |||||||||||||||
| Systems | 2,366 | 187 | 4,033 | 2,087 | |||||||||||
| Disposables, service and accessories | 1,853 | 1,002 | 3,594 | 2,016 | |||||||||||
| Total cost of revenue | 4,219 | 1,189 | 7,627 | 4,103 | |||||||||||
| Gross margin | 4,579 | 3,313 | 8,643 | 7,279 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 1,777 | 2,273 | 4,127 | 4,516 | |||||||||||
| Sales and marketing | 3,269 | 3,301 | 6,417 | 6,304 | |||||||||||
| General and administrative | 4,002 | 3,760 | 8,497 | 7,226 | |||||||||||
| Other | (492 | ) | - | (492 | ) | - | |||||||||
| Total operating expenses | 8,556 | 9,334 | 18,549 | 18,046 | |||||||||||
| Operating loss | (3,977 | ) | (6,021 | ) | (9,906 | ) | (10,767 | ) | |||||||
| Other expense | (1 | ) | (3 | ) | (1 | ) | (3 | ) | |||||||
| Interest income, net | 152 | 191 | 258 | 430 | |||||||||||
| Net loss | $ | (3,826 | ) | $ | (5,833 | ) | $ | (9,649 | ) | $ | (10,340 | ) | |||
| Cumulative dividend on convertible preferred stock | (318 | ) | (325 | ) | (632 | ) | (656 | ) | |||||||
| Net loss attributable to common stockholders | $ | (4,144 | ) | $ | (6,158 | ) | $ | (10,281 | ) | $ | (10,996 | ) | |||
| Net loss per share attributed to common stockholders: | |||||||||||||||
| Basic | $ | (0.05 | ) | $ | (0.07 | ) | $ | (0.12 | ) | $ | (0.13 | ) | |||
| Diluted | $ | (0.05 | ) | $ | (0.07 | ) | $ | (0.12 | ) | $ | (0.13 | ) | |||
| Weighted average number of common shares and equivalents: | |||||||||||||||
| Basic | 87,952,086 | 84,570,738 | 87,861,231 | 84,025,335 | |||||||||||
| Diluted | 87,952,086 | 84,570,738 | 87,861,231 | 84,025,335 | |||||||||||
| STEREOTAXIS, INC. | |||||||
| CONSOLIDATED BALANCE SHEETS | |||||||
| (in thousands, except share amounts) | June 30, 2025 | December 31, 2024 | |||||
| (Unaudited) | |||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 6,967 | $ | 12,217 | |||
| Restricted cash - current | - | 219 | |||||
| Accounts receivable, net of allowance of | 4,393 | 3,824 | |||||
| Inventories, net | 9,608 | 8,331 | |||||
| Prepaid expenses and other current assets | 936 | 1,848 | |||||
| Total current assets | 21,904 | 26,439 | |||||
| Property and equipment, net | 3,284 | 3,573 | |||||
| Goodwill | 3,764 | 3,764 | |||||
| Intangible assets, net | 6,899 | 7,358 | |||||
| Operating lease right-of-use assets | 5,204 | 5,483 | |||||
| Prepaid and other non-current assets | 118 | 107 | |||||
| Total assets | $ | 41,173 | $ | 46,724 | |||
| Liabilities and stockholders' equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 6,730 | $ | 5,668 | |||
| Accrued liabilities | 1,731 | 2,922 | |||||
| Deferred revenue | 5,843 | 6,804 | |||||
| Current contingent consideration | 5,839 | 5,638 | |||||
| Current portion of operating lease liabilities | 605 | 570 | |||||
| Total current liabilities | 20,748 | 21,602 | |||||
| Long-term deferred revenue | 1,057 | 2,064 | |||||
| Long-term contingent consideration | 6,384 | 6,126 | |||||
| Operating lease liabilities | 5,122 | 5,436 | |||||
| Other liabilities | 1,110 | 64 | |||||
| Total liabilities | 34,421 | 35,292 | |||||
| Series A - Convertible preferred stock: | |||||||
| Convertible preferred stock, Series A, par value | 5,296 | 5,352 | |||||
| Stockholders' equity: | |||||||
| Common stock, par value | 86 | 85 | |||||
| Additional paid-in capital | 572,950 | 567,926 | |||||
| Treasury stock, 4,015 shares at 2025 and 2024 | (206 | ) | (206 | ) | |||
| Accumulated deficit | (571,374 | ) | (561,725 | ) | |||
| Total stockholders' equity | 1,456 | 6,080 | |||||
| Total liabilities and stockholders' equity | $ | 41,173 | $ | 46,724 | |||
FAQ
What were Stereotaxis (STXS) Q2 2025 earnings results?
How much cash does Stereotaxis (STXS) have after its recent financing?
What is Stereotaxis' (STXS) revenue guidance for 2025?
What was the significance of MAGiC Sweep FDA clearance for Stereotaxis (STXS)?
What were Stereotaxis' (STXS) gross margins in Q2 2025?
